Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
about
Overview of current immunotherapeutic strategies for gliomaDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsUbiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junctionBiodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivoEphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelAdenoviral vector-mediated gene therapy for gliomas: coming of age.Current status of gene therapy for brain tumors.Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Trial watch: Naked and vectored DNA-based anticancer vaccinesPlasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialAdenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaPreclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelRecent advances and future of immunotherapy for glioblastoma.Improved Adeno-associated Viral Gene Transfer to Murine Glioma.Long-term expression of rAAV2-hIL15 enhances immunoglobulin production and lymphokine-activated killer cell-mediated human glioblastoma cell death.Glioma virus therapies between bench and bedside.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for gliomaClinical trials of viral therapy for malignant gliomas.Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions.Klotho regulates postnatal neurogenesis and protects against age-related spatial memory loss.Nanotherapeutic systems for local treatment of brain tumors.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Development of preclinical models for immunogene therapy of brain cancer: it's not monkey business!Transcriptomic signatures of cellular and humoral immune responses in older adults after seasonal influenza vaccination identified by data-driven clustering.Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.
P2860
Q26776345-3265261C-B66E-4F11-8980-9F7C90DFBFA8Q27014829-46F93E75-C325-41F0-A93C-B6BADCA42116Q30646859-34979160-CEE8-4E96-83E0-B75B509D25FFQ33716020-44F94D81-A2A7-49D1-AB4C-09FDCC53F4BBQ33924763-8681F0BB-E6C8-4A21-89D2-C2C3ED383504Q34022048-B089648B-BEC3-4C88-8EA7-CA3F9ED8EB15Q34318157-97E91109-F264-4F50-A83E-F55331270968Q34347733-CDC8E2EF-0086-45DD-AE4C-DCBB33321F35Q35527165-3551221F-4E24-4494-BE44-CF63167FF055Q35798986-EC7A2D40-DE19-490A-9B19-93C38EFF54B0Q36200438-3E5AF7C1-BB02-4E26-A861-DA1D9916427FQ36367568-0EF7D243-94C1-49A0-AA53-14DDE52E01DCQ36534329-58843E0C-9266-4ADD-86C8-629D2B1CE3F5Q36659314-035EFF04-86FB-4BD2-B56C-55764939FF47Q36811505-42442B11-68B7-47F0-96AA-C665B143D188Q37050094-8DEB0154-8348-48C2-8B52-6A57D628DB76Q37239071-BD291747-DCC1-40D8-942B-45A189DCB75BQ37366610-D0E97468-14FA-489B-8570-FDA4A5FFB72DQ37562496-32B77EE7-77EB-47B0-813E-E122B3603485Q37580510-2FCE2875-93F5-440B-92AC-FA9187597CC8Q37730116-A7F30B42-6517-4EE5-844A-701FD2B5B42DQ38153777-648EA448-BA53-4801-B449-562985FB8BC4Q38402828-6E9D8908-1482-4E30-A16C-5B8D436CB207Q38609968-5D02C6BE-32D0-44B3-9057-F9D037890678Q39330269-29FED9D7-0DAF-4428-910F-088BB1BA227CQ41189810-A2BAC269-7C74-4557-9155-269F86E196DEQ41922812-C6F9841D-58A4-4D9A-8B78-9FDBA84E34F8Q47563152-5E1E8445-8F66-43D0-A93E-3632E5337BF2Q53826191-0E67E7D9-B6EE-4EB6-9ADA-B794219ABCAE
P2860
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@ast
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@en
type
label
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@ast
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@en
prefLabel
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@ast
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@en
P2093
P2860
P356
P1433
P1476
Combined Flt3L/TK gene therapy ...... rogate brain tumor neoantigen.
@en
P2093
A K M Ghulam Muhammad
Chunyan Liu
Daniel Larocque
Gwendalyn D King
Kurt M Kroeger
Kyle R Kelson
Maria G Castro
Nicholas S R Sanderson
Pedro R Lowenstein
Weidong Xiong
P2860
P304
P356
10.1038/MT.2011.77
P577
2011-04-19T00:00:00Z